^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
inecalcitol (TX-522)
i
Other names: TX-522, TX 522, SDB-112
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Hybrigenics
Drug class:
Calcitriol receptor agonist
Related drugs:
over3years
The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer. (PubMed, Front Endocrinol (Lausanne))
Furthermore, in vivo validation in a MCF7 cell line-derived xenograft mouse model decreased tumor growth and cell cycle progression after combination therapy, but not in a TNBC BT20 cell line-derived xenograft model. In conclusion, we show that addition of a potent vitamin D analog to selective CDK4/6 inhibitor treatment results in increased antiproliferative effects in ER BC both in vitro and in vivo.
Preclinical • Journal
|
CDK2 (Cyclin-dependent kinase 2) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
|
Ibrance (palbociclib) • inecalcitol (TX-522)
Share via
